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eproducibility  of  biomedical  research  –  The  importance  of  editorial
igilance
a  b  s  t  r  a  c  t
any  journal  editors  are  a failing  to implement  their  own  authors’  instructions,  resulting  in  the publication  of  many  articles  that do  not  meet  basic
tandards  of  transparency,  employ  unsuitable  data  analysis  methods  and  report  overly  optimistic  conclusions.  This  problem  is particularly  acute  where
uantitative  measurements  are  made  and  results  in  the  publication  of  papers  that  lack  scientiﬁc  rigor and  contributes  to the  concerns  with  regard  to  the
eproducibility  of  biomedical  research.  This hampers  research  areas  such  as  biomarker  identiﬁcation,  as  reproducing  all but the  most  striking  changes  is
hallenging  and  translation  to  patient  care  rare.
© 2017  Published  by  Elsevier  GmbH.  This  is an  open  access  article  under  the  CC BY-NC-ND  licenseConcern at the robustness, reliability and relevance of much
olecular biomedical research has been mounting for at least
0 years. Sporadic warnings about the lack of reliable qual-
ty control procedures in molecular diagnostics [1], reports of
ross-contamination of tissue cultures [2] and evidence for
etween-study heterogeneity of genetic association studies for dis-
ase outcome [3] have been reinforced by numerous investigations
hat expose a lack of reproducibility of much basic and preclinical
esearch and identify the accompanying huge waste of research
unding (reviewed in [4]).
There are many reasons for this serious situation [5], but one of
he most critical factors is the lack of transparency in the reporting
f experimental detail [6,7], which makes it difﬁcult for reviewers
nd readers alike to judge the validly of the data and conclusions
resented in many papers. This problem, which is probably more
ne of omission that deliberate, has led to solutions being proposed
n how to deal with this challenge; for example, there are sug-
estions for improved training of researchers, enhanced emphasis
n appropriate study design, easier access to unpublished primary
ata and open public discussion of published research [8]. Undoubt-
dly there is a need to encourage changes in investigator attitude,
oth in terms of validating reagents and understanding that ambi-
uity is intrinsic to biological systems [9]. Furthermore, there needs
o more of an appreciation that choice of methods for sample prepa-
ation and measurement can contribute substantially to technical
ariance and/or bias. This is rarely a consideration when quantify-
ng nucleic acids, yet can be major reason for poor reproducibility.
There have also been moves towards urging the research
ommunity to implement guidelines for the appropriate design,
xecution and reporting of research methods. There are now a
umber of guidelines, starting with the MIAME  guidelines pro-
iding minimal information about microarray experiments [10],
inimum information speciﬁcations for in situ hybridisation and
mmunohistochemistry experiments (MISFISHIE) [11], through
ttp://dx.doi.org/10.1016/j.bdq.2017.01.002
214-7535/© 2017 Published by Elsevier GmbH. This is an open access article under the C(http://creativecommons.org/licenses/by-nc-nd/4.0/).
MIQE [6] and digital MIQE [12] guidelines for real time quanti-
tative PCR (qPCR) and digital PCR (dPCR), respectively, to those
dealing with standards for reporting in vivo animal research [13]
and pathology data gathered from animal tissues [14].
Nevertheless, it is also clear that whilst the existence of guide-
lines is useful, they are only part of the solution [15]. For one,
although adherence places additional burdens on the researcher
in terms of additional cost and effort, failure to observe basic stan-
dards of transparency has few immediate consequences, especially
with regards to publication. For example, whilst there have been
discussions on the need to improve the publication validation pro-
cess [16,17] and journal editors have acknowledged that they have
failed in their responsibility to monitor the quality of technical
information provided and promise to address these issues [16–27]
there is considerable evidence that this talk has not necessarily
been followed by much action [4]. This is perhaps not surprising
in light of their earlier failure to ensure that authors comply with
primary data availability required by their own author instructions
[28].
This failure is perhaps best demonstrated using an illustrative
example that is representative of the types of technical errors
and omissions typically found in the biomedical literature. qPCR
is probably the most widely used enabling technology in molecu-
lar research [29] and results obtained using reverse transcription
(RT) of cellular RNA followed by simultaneous ampliﬁcation and
detection of PCR amplicons has been used in tens of thousands of
papers to investigate changes in RNA expression levels [30]. It is
also a good example of a technology that has been subjected to
extensive scrutiny and found to be seriously deﬁcient in design,
reporting and analysis [31–41]. A detailed analysis of around 2000
peer-reviewed publications found that the vast majority of papers
do not report sufﬁcient technical detail and use inappropriate or
misleading data analysis methods [42]. This has been conﬁrmed
by follow-up studies [4,15,43–46]. But perhaps a more tangeable
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etric is that, despite the tens of thousands of research papers that
ave used RT-qPCR to quantify RNA expression over the last 20
ears, the number of clinical tests developed measuring cellular
NAs to guide medical treatment can be counted in the ones.
In its 2013 announcement acknowledging that journals such as
ature contribute to “failures in the reliability and reproducibility
f published research”, the editors admit that journals “compound”
hem by failing to “exert sufﬁcient scrutiny” and not publishing
enough information for other researchers to assess results prop-
rly” [18]. Yet they do not appear to be implementing resolutions
o rectify failings. A paper published in a top nature journal in the
ast two months demonstrates a recent example of this failure. The
anuscript, which we will not name, lacks the most basic informa-
ion required to assess the validity of the experimental protocols,
ontains critical, yet basic errors that should have been detected
uring the review process, and makes conclusions based on results
hat are probably ﬂawed.
 The qPCR protocol published in the supplementary informa-
tion is limited to six lines and provides no information about
RNA integrity, quality or quantity used or the conditions of the
reverse transcription or qPCR efﬁciency. This is despite a wealth
of published evidence that highlights the importance of RNA
quality [47,48], the variability of the RT step [49–51] and the
importance of appropriate PCR conditions [52–55] for achieving
reliable results.
 Data analysis was performed using a less accurate approach, as
the chosen method [56] requires an invalid assumption of 100%
PCR ampliﬁcation efﬁciency across all assays and directly com-
pares the difference in Cqs of different primer sets (a number
that will vary with threshold settings if, as is often the case, the
assays have different shaped ampliﬁcation plots). That approach
was superseded by a method that only compares the same assay
between different samples and factors in the PCR efﬁciency to
provide a far more accurate estimation of the differences [57,58].
The authors use a single, unvalidated reference gene for normal-
sation, an approach shown to be inappropriate as far back as 2002
59]. How do the authors know the reference gene is not effected
y the study?
The reference gene in question, -actin, is not an ideal reference
ene in the model investigated in this study as it was reported to
ave “a tendency to be down regulated” in the same types of tumour
amples [60].
 An analysis of the primer sequences published in the supple-
mentary information using PrimerBlast ﬁnds no target templates
for the one of the primer pairs. A BLAST search ﬁnds no 100%
sequence identity of another forward primer with any target,
whereas the reverse primer has 100% sequence identity with
a different, unrelated human mRNA; the study used a mouse
model. Another reverse primer has a single mismatch with all
published target sequences. Yet another primer pair targeting a
speciﬁc transcript splice variant has sufﬁcient sequence identity
with all other variants to suggest it is not speciﬁc at all and could
also amplify the other variants.
 While some of these observations may  be less critical if the
reported expression changes differed by orders of magnitude,
conclusions are drawn on the published qPCR based on 3–5-fold
differences that are well within the variability range established
for the reverse transcription step [51].Whilst such differences are measureable using RT-qPCR, with
he points highlighted above, doubt is introduced to the conclusions
ssociated with this technique and, arguably far worse, with the
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sible to reproduce the study to corroborate the ﬁndings. Yet it will
not take the reader long, should they be so inclined, to ﬁnd numer-
ous published studies, where these omissions apply, frequently
purporting to ﬁnd differences of less than two-fold, a feat that,
without the most rigorous selection of multiple reference genes,
is simply impossible to achieve with any degree of accuracy.
These parameters are elemental for qPCR and it is extraordinary
that such lacks of adherence have been allowed to slip through
the vetting process. It is truly astonishing that this is but one of
hundreds, if not thousands of publications utilising qPCR that are
published with similar shortcomings. Biomolecular Detection and
Quantiﬁcation (BDQ) was conceived as a journal committed to pub-
lishing molecular studies that adhere to best practice in the areas of
study design, measurement, data analysis and reporting. As editors,
we handle numerous manuscript and a continuous theme is the ini-
tial absence of comprehensive information on aspects of the work
being reported. This is corrected in papers published by this journal,
but clearly is not done so by the editors of many other journals. It
is unfortunate that the editors of Nature, and many other journals,
continue to publish papers that have not been adequately reviewed
and where the information provided does not follow Nature’s own
recommendations. Is it a surprise that we continue to face a crisis of
reproducibility and that so many papers are published that report
results that are meaningless?
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